Vanguard discloses zero Pulmonx holdings after internal realignment (NASDAQ: LUNG)
Rhea-AI Filing Summary
The Vanguard Group filed an amended Schedule 13G/A reporting that it beneficially owns 0 shares of Pulmonx Corp Common Stock (CUSIP 745848101). The filing states this follows an internal realignment effective January 12, 2026 under SEC Release No. 34-39538, which resulted in certain Vanguard subsidiaries reporting ownership separately. The filing lists the filer address as 100 Vanguard Blvd., Malvern, PA and is signed by Ashley Grim on 03/27/2026.
Positive
- None.
Negative
- None.
Insights
Vanguard reports no beneficial ownership in Pulmonx after an internal reorganization.
The filing documents an internal realignment dated January 12, 2026, citing SEC Release No. 34-39538, and states Amount beneficially owned: 0 and Percent of class: 0%.
Cash-flow treatment and any holdings now reported by specific Vanguard subsidiaries are not listed in this excerpt; subsequent filings by those separate entities could show redistributed positions.
FAQ
Does The Vanguard Group own Pulmonx (LUNG) shares according to this filing?
Why does Vanguard report zero ownership in this Schedule 13G/A?
Who signed the Schedule 13G/A for The Vanguard Group reporting Pulmonx ownership?
What address is listed for The Vanguard Group on this filing?
Does this filing show holdings by Vanguard subsidiaries after the realignment?